1980
Smoking abstinence and small cell lung cancer survival. An association.
Johnston-Early A, Cohen M, Minna J, Paxton L, Fossieck B, Ihde D, Bunn P, Matthews M, Makuch R. Smoking abstinence and small cell lung cancer survival. An association. JAMA 1980, 244: 2175-9. PMID: 6252357, DOI: 10.1001/jama.244.19.2175.Peer-Reviewed Original ResearchConceptsSmall cell lung cancerCell lung cancerSS patientsLung cancerCell lung cancer survivalThymosin fraction V.Lung cancer survivalDiscontinuation of smokingStart of treatmentContinuation of smokingSurvival benefitCigarette smokingPoor prognosisPrognostic implicationsCancer survivalSurvival differencesRadiation therapyBetter survivalPatientsSmokingBeneficial effectsS groupDiagnosisSurvivalTherapy
1979
EFFECTS OF THYMOSIN IN VITRO IN CANCER PATIENTS AND CORRELATION WITH CLINICAL COURSE AFTER THYMOSIN IMMUNOTHERAPY
Chretien P, Lipson S, Makuch R, Kenady D, Cohen M. EFFECTS OF THYMOSIN IN VITRO IN CANCER PATIENTS AND CORRELATION WITH CLINICAL COURSE AFTER THYMOSIN IMMUNOTHERAPY. Annals Of The New York Academy Of Sciences 1979, 332: 135-147. PMID: 316979, DOI: 10.1111/j.1749-6632.1979.tb47107.x.Peer-Reviewed Original ResearchThymosin fraction V and intensive combination chemotherapy. Prolonging the survival of patients with small-cell lung cancer.
Cohen M, Chretien P, Ihde D, Fossieck B, Makuch R, Bunn P, Johnston A, Shackney S, Matthews M, Lipson S, Kenady D, Minna J. Thymosin fraction V and intensive combination chemotherapy. Prolonging the survival of patients with small-cell lung cancer. JAMA 1979, 241: 1813-5. PMID: 219267, DOI: 10.1001/jama.241.17.1813.Peer-Reviewed Original ResearchConceptsThymosin fraction VIntensive remission induction chemotherapySmall cell bronchogenic carcinomaSmall cell lung cancerComplete response rateRemission induction chemotherapyWeeks of chemotherapyIntensive combination chemotherapySurvival of patientsRelapse-free survivalThymosin administrationThymosin treatmentComplete respondersCombination chemotherapyBronchogenic carcinomaImmune deficitsLung cancerSurvival durationSurvival timeTreatment groupsResponse rateChemotherapyPatientsFraction VTreatmentThymosin immunotherapy in patients with small cell carcinoma of the lung. Correlation of in vitro studies with clinical course
Lipson S, Chretien P, Makuch R, Kenady D, Cohen M. Thymosin immunotherapy in patients with small cell carcinoma of the lung. Correlation of in vitro studies with clinical course. Cancer 1979, 43: 863-870. PMID: 218717, DOI: 10.1002/1097-0142(197903)43:3<863::aid-cncr2820430313>3.0.co;2-5.Peer-Reviewed Original ResearchConceptsTotal T cellsPretreatment CEA levelsT cellsCEA levelsClinical courseCellular immunityTumor responsePretreatment levelsCarcinoembryonic antigenAdministration of thymosinIntensive chemotherapy programsPeripheral blood levelsSmall cell carcinomaDuration of responseOverall tumor responseThymus-dependent lymphocytesLarger patient populationType of treatmentP groupMechanism of actionComplete remissionT60 groupChemotherapy programBronchogenic carcinomaImmune defects
1978
Thymosin in cancer patients: in vitro effects and correlations with clinical response to thymosin immunotherapy.
Chretien P, Lipson S, Makuch R, Kenady D, Cohen M, Minna J. Thymosin in cancer patients: in vitro effects and correlations with clinical response to thymosin immunotherapy. Journal Of The National Cancer Institute 1978, 62: 1787-90. PMID: 215307.Peer-Reviewed Original Research